In Vitro and In Silico Assessments of Curcuminoids and Turmerones from Curcuma longa as Novel Inhibitors of Leishmania infantum Arginase
<b>Background/Objectives</b>: The anti-<i>Leishmania</i> potential of <i>Curcuma longa</i> and its derivatives, such as curcuminoids, is well-established, yet their mechanisms of action remain underexplored. This study investigates the inhibitory effects of <i>C. longa</i> extracts and curcumin on <i>Leishmania infantum</i> arginase, a key enzyme in polyamine and trypanothione biosynthesis, and evaluates their antiparasitic activity. <b>Methods</b>: Extracts were prepared via rhizome successive maceration with hexane (HEXCURC), dichloromethane (DCCURC), and ethanol (ETOHCURC) and chemically characterized by a combination of chromatographic and spectrometric methods. The inhibition of recombinant <i>L. infantum</i> arginase (<i>Li</i>ARG) was assessed by urea quantification, while molecular docking explored interactions between the main compounds annotated in the extracts and the enzyme's active site. Biological activity was tested against <i>L. infantum</i> promastigotes, intracellular amastigotes, and mammalian cells. <b>Results</b>: LC-MS and GC-MS revealed curcuminoids and turmerones as main compounds annotated in the extracts. DCCURC, HEXCURC, and curcumin showed the strongest <i>Li</i>ARG inhibition (IC<sub>50</sub> = 10.04, 14.4, and 17.55 μg/mL, respectively). Docking analysis revealed that curcumin, demethoxycurcumin, and bisdemethoxycurcumin bind near the active site, with binding energies of -3.43, -4.14, and -3.99 kcal/mol, respectively. Curcumin demonstrated superior anti-promastigote activity (IC<sub>50</sub> = 15.01 μg/mL) and selectivity (SI = 12.7) compared to the extracts. It also significantly reduced amastigote burden in infected macrophages (IC<sub>50</sub> = 13.6 μg/mL). <b>Conclusions</b>: This is the first report demonstrating that <i>C. longa</i> extracts and curcumin inhibit <i>Li</i>ARG. These findings support curcumin's potential as a lead compound for developing multi-target therapies against leishmaniasis, combining enzyme inhibition with direct antiparasitic effects.
Authors
- Ana Cláudia F. Amaral (ORCID: https://orcid.org/0000-0002-2532-471X)
- M. A. Mpalantinos
- Emiliano Barreto (ORCID: https://orcid.org/0000-0002-4956-5075)
- Igor A. Rodrigues (ORCID: https://orcid.org/0000-0001-9432-3991)
- Alessandra Mendonça Teles de Souza (ORCID: https://orcid.org/0000-0001-9986-405X)
- Andreza R. Garcia (ORCID: https://orcid.org/0000-0001-8623-1659)
- Carlos Rangel Rodrigues (ORCID: https://orcid.org/0000-0001-8453-7654)
- Bárbara Abrahim-Vieira (ORCID: https://orcid.org/0000-0001-6444-0169)
- Dirlei Nico (ORCID: https://orcid.org/0000-0002-6129-1142)
- Jefferson Rocha de Andrade Silva (ORCID: https://orcid.org/0000-0003-2569-1306)
- Anderson S. Pinheiro (ORCID: https://orcid.org/0000-0001-5118-6931)
- Raissa Alves da Conceição (ORCID: https://orcid.org/0000-0001-8264-7673)
- Flora Fernanda Schulze Spíndola
- Walter Sotto M. Fernandes Neto
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Fundação Oswaldo Cruz (BR)
- Universidade Federal do Amazonas (BR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3390/ph18060851
- Primary Topic
- Research on Leishmaniasis Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Universidade Federal do Rio de Janeiro